Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients
Received 23 February 2018
Accepted for publication 25 May 2018
Published 31 July 2018 Volume 2018:11 Pages 4443—4447
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
Chagkrit Ditsatham,1 Imjai Chitapanarux,2–4 Areewan Somwangprasert,1 Kirati Watcharachan,1 Panchaporn Wongmaneerung,1 Chaiyut Charoentum,5 Busyamas Chewaskulyong,5 Somvilai Chakrabandhu,2 Wimrak Onchan,2 Anongnart Teeyasuntranonn,6 Patumrat Sripan3
1Division of Head Neck Breast Surgery, 2Division of Radiation Oncology, 3Northern Thai Research Group of Radiation Oncology, 4Chiang Mai Cancer Registry, Maharaj Nakorn Chiang Mai Hospital, 5Division of Oncology, 6Pharmacy Division, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Background: We report the safety and efficacy of eribulin as a late treatment line in Thai metastatic breast cancer (MBC) patients.
Patients and methods: A total of 30 MBC patients treated with eribulin between January 2014 and January 2017 were retrospectively analyzed. The patients were scheduled to receive 1.4 mg/m2 of eribulin on day 1, day 8 and subsequently every 21 days. All patients had previously received at least three chemotherapy regimens including anthracycline and taxane. Response rate and progression-free survival (PFS) were analyzed.
Results: The median age was 56 years (range, 40–74 years), with a median follow-up time of 5.7 months (range, 0.2–25 months). The overall response rate was 30% (nine patients): four patients had triple-negative breast cancer, three patients had luminal B breast cancer and two patients had luminal A breast cancer. The median PFS was 2.9 months (range, 0.2–14 months). The median number of previous chemotherapy regimens was 4 (range, 3–9). Univariate analysis showed that the number of regimens (four or fewer) prior to eribulin was statistically associated with superior PFS (P = 0.009). Multivariate analysis also showed similar statistical association between number of prior regimens (four or fewer) and better PFS adjusted by age group (≥50 years; hazard ratio = 1.29; 95% CI: 1.0–1.65; P = 0.046). There were no toxic deaths or grade 4 toxicities. Nine (30%) patients had grade 3 anemia toxicities, and the other common toxicities were leukopenia and neutropenia. Four (13%) patients required dose reduction and 16 (53%) patients required dose delay because of toxicities.
Conclusion: Eribulin is an effective drug for heavily pretreated MBC patients with tolerable toxicities. The benefit was superior in patients who received fewer than four previous chemotherapy regimens.
Keywords: eribulin, metastatic breast cancer, late treatment line
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]